ARTUR JAVMEN, AUSRA NEMEIKAITE-CENIENE, SAULIUS GRIGISKIS, IRENA JONAUSKIENE, MARK RUDENKOV, DARIUS KACIANAUSKAS, MYKOLAS MAURICAS

S. cerevisiae $\beta$-glucan reduced viability of mouse hepatoma cells in vitro

$\beta$-Glucan is a natural polymer, which is widely studied due to its multiple immunomodulatory properties. In addition, recent findings indicate potent antitumor properties of $\beta$-glucan. Saccharomyces cerevisiae, baker's yeast, is one of the commonly used sources of $\beta$-1,3-glucan. The aim of this work was to investigate S. cerevisiae $\beta$-glucan immunomodulatory activity against cancer cells.In our experiments, BALB/c mice were fed with insoluble whole $\beta$-glucan particles, and then their blood was collected for experiments. MH-22a hepatoma cells were treated with the blood of mice fed with $\beta$-glucan, and tumor cell viability was investigated after the treatment.The obtained results demonstrated that leukocytes in vivoprimed with whole glucan particles, in combination with soluble $\beta$-glucan, decreased MH-22a hepatoma cell viabilityin vitro.Our study has indicated that $\beta$-glucan obtained from S. cerevisiae potentially primes mouse whole blood leukocytes to induce cell death of mouse hepatoma cells.

S. cerevisiae $\beta$-glucan reduced viability of mouse hepatoma cells in vitro

Keywords:

$\beta$-Glucan, yeast, cancer, mice,

PDF

___

Budak F, Göral G, Oral HB (2008). Saccharomyces cerevisiae beta- glucan induces interferon-gamma production in human T cells via IL-1. Turk J Immunol 13: 21–26.

Chan GC, Chan WC, Man-Yuen SDD (2009). The effects of β-glucan on human immune and cancer cells. J Hematol Oncol 2: 25.

Driscoll M, Hansen R, Ding C, Cramer DE, Yan J (2009). Therapeutic potential of various beta-glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy. Cancer Biol Ther 8: 218–225.

Gelderman KA, Tomlinson S, Ross GD, Gorter A (2004). Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 25: 158–164.

Grellier P, Nemeikaitė-Čėniene A, Šarlauskas J, Čėnas N (2008). Role of single-electron oxidation potential and lipophilicity in the antiplasmodial in vitro activity of polyphenols: comparison to mammalian cells. Z Naturforsch C 63: 445–450.

Hunter JKW, Gault RA, Berner MD (2002). Preparation of microparticulate β-glucan from Saccharomyces cerevisiae for use in immune potentiation. Lett Appl Microbiol 35: 267–271.

Javmen A, Grigiškis S, Gliebutė R (2012). β-Glucan extraction from Saccharomyces cerevisiae yeast using Actinomyces rutgersensis 88 yeast lyzing enzymatic complex. Biologija 58: 51–59.

Javmen A, Grigiškis S, Rudenkov M, Mauricas M (2013a). Purification and partial characterization of a novel β-1,3-endoglucanase from Streptomyces rutgersensis. Protein J 32: 411–417.

Javmen A, Grigiškis S, Rudenkov M, Pelišauskaitė E (2013b). Saccharomyces cerevisiae yeast growth conditions optimisation using RSM methodology for the production of β-glucan. Minerva Biotecnol 25: 227–234.

Lee JN, Lee DY, Ji IH, Kim GE, Kim HN, Sohn J, Kim S, Kim CW (2000). Purification of soluble beta-glucan with immune- enhancing activity from the cell wall of yeast. Biosci Biotechnol Biochem 65: 837–841.

Li B, Allendorf DJ, Hansen R, Marroquin J, Cramer EC, Harris LC, Yan J (2007). Combined yeast β-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay accelerating factor CD55. Cancer Res 67: 7421–7430.

Li B, Allendorf DJ, Hansen R, Marroquin J, Ding C, Cramer EC, Yan J (2006). Yeast β-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk- phosphatidylinositol 3-kinase pathway. J Immunol 177: 1661– 1669.

Mantovani MS, Bellini MF, Angeli JPF, Oliveira RJ, Silva AF, Ribeiro LR (2008). β-Glucans in promoting health: prevention against mutation and cancer. Mutat Res 658: 154–161.

Marakalala MJ, Williams DL, Hoving JC, Engstad R, Netea MG, Brown GD (2013). Dectin-1 plays a redundant role in the immunomodulatory activities of β-glucan-rich ligands in vivo. Microb Infect 15: 511–515.

Nemeikaitė-Čėnienė A, Dringelienė A, Šarlauskas J, Čėnas N (2005). Role of NAD(P)H: quinone oxidoreductase (NQO1) in apoptosis induction by aziridinylbenzoquinones RH1 and MeDZQ. Acta Bioch Pol 52: 937–941.

Novak M, Vetvicka V (2008). β-Glucans, history and the present: immunomodulatory aspects and mechanisms of action. J Immunotoxicol 5: 47–57.

Novak M, Vetvicka V (2009). Glucans as biological response modifiers. Endocr Metab Immune Disord Drug Targets 9: 67–75.

Obakan P, Alkurt G, Köse B, Çoker Gürkan A, Arısan ED, Coşkun D, Ünsal ZN (2014). Downregulation of c-Myc mediated ODC expression after purvalanol treatment is under control of upstream MAPK signaling axis in MCF-7 breast cancer cells. Turk J Biol 38: 867–879.

Pelizon AC, Kaneno R, Soares AMVC, Meira DA, Sartori A (2005). Immunomodulatory activities associated with β-glucan derived from Saccharomyces cerevisiae. Physiol Res 54: 557– 564.

Petravić-Tominac V, Zechner-Krpan V, Grba S, Panjkota-Krbavčić I, Vidović L (2010). Biological effects of yeast β-glucans. Agric Conspec Sci 75: 149–158.

Prabhu A, Venkat P, Gajaraj B, Kilingar Nadumane V (2014). Induction of apoptosis in the cervical cancer cell line HeLa by a novel metabolite extracted from the fungus Aspergillus japonicus Saito. Turk J Biol 38: 922–929.

Shokri H, Asadi F, Khosravi AR (2008). Isolation of β-glucan from the cell wall of Saccharomyces cerevisiae. Natur Prod Res 22: 414–421.

Shvenberger IN, Alexandrova SA (2000). PCR detected genome polymorphism in malignant cell growth. Int Rev Cytol 199: 117–159.

Vetvicka V (2011). Glucan—immunostimulant, adjuvant, potential drug. World J Clin Oncol 2: 115–119.